ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2015, Vol. 7 ›› Issue (6): 551-553.doi: 10.3969/j.issn.1674-3865.2015.06.006

• 临床研究 • 上一篇    下一篇

盐酸氨溴索治疗足月重度窒息新生儿急性呼吸窘迫综合征的疗效观察

刘小娟   

  1. 744300 甘肃 平凉,甘肃省泾川县人民医院儿科
  • 出版日期:2015-12-25 发布日期:2018-11-19
  • 作者简介:刘小娟(1978-),女,主治医师。研究方向:新生儿疾病的诊断与治疗,E-mail:1697062208@qq.com

Ambroxol hydrochloride in the treatment of acute respiratory distress syndrome in the term newborns with severe asphyxia

LIU Xiaojuan   

  1. Jingchuan County, Gansu Province People's Hospital, Pingliang 744300,China
  • Online:2015-12-25 Published:2018-11-19

摘要:
目的: 观察盐酸氨溴索治疗足月重度窒息新生儿呼吸窘迫综合征(ARDS)的临床效果。
方法: 甘肃省泾川县人民医院儿科2012-10/2014-10收治60例重度窒息新生儿ARDS患儿,随机分为对照组28例和观察组32例。对照组采用基础疗法进行治疗,观察组在对照组治疗基础上联合盐酸氨溴索进行治疗。观察两组患儿呼吸窘迫缓解时间及2周时新生儿行为神经测定(NBNA)结果;临床死亡率、缺氧并发症情况、机械通气情况、2 d时胸部X线好转情况。
结果: 观察组患儿呼吸窘迫症状缓解时间为(4.0±1.1)d,低于对照组(7.0±1.5)d,2周时NBNA评分为(38.15±3.50)分,高于对照组(35.49±2.19)分,差异有统计学意义(P<0.05)。观察组临床出现并发症的概率、患儿临床死亡率、机械通气率均低于对照组,2 d时胸部X线好转率高于对照组,差异有统计学意义(P<0.05)。
结论: 盐酸氨溴索治疗重度窒息ARDS患儿能够显著改善呼吸窘迫症状时间,降低ARDS患儿临床出现并发症的概率以及疾病的死亡率,最终显著提高患儿的生活质量。

关键词: 呼吸窘迫综合征, 窒息, 盐酸氨溴索, 治疗应用, 婴儿, 新生

Abstract:
Objective:To observe the clinical effect of ambroxol hydrochloride in the treatment of acute respiratory distress syndrome(ARDS) in term neonates with several asphyxia.Methods:A total of 60 severe asphyxia neonates with ARDS admitted to Jingchuan People's Hospital of Gansu Province from October 2012 to October 2014 were randomly divided into two groups:28 cases in control group and 32 cases in observation group. The control group was given basic treatment, and the observation group was treated with ambroxol hydrochloride in addition to the basic treatment. Observe the time for respiratory distress to get relieved and the NBNA at the end of two weeks of treatment in the two groups. The clinical mortality, complications due to hypoxia, mechanical ventilation and improvement on chest Xray at two days were also observed.
Results:The relief time in the observation group was (4.0±1.1)d,which was shorter than that of the control group[(7.0±1.5)d]. The NBNA score at two weeks was 38.15±3.50,which was higher than the control group(35.49±2.19),the difference being of statistical significance(P<0.05).The occurrence rate of complications,clinical mortality and rate of mechanical ventilation in the observation group were all lower than those of the control group,and the rate of improvement on chest Xray at two days was higher than the control group,all the differences being of statistically significance(P<0.05).
Conclusion:In the treatment of ARDS children with severe asphyxia,ambroxol hydrochloride can significantly shorten the time for distress symptoms to get relieved,reduce the complication rate and mortality,resulting in the improvement of the child patients.

Key words: Respiratory distress syndrome;Asphyxia, Ambroxol hydrochloride, therapeutic application, Infant, Newborns